What Are the GMP Inspection Requirements for Foreign Drug Factories in China?

For foreign pharmaceutical manufacturers seeking to supply the Chinese market, compliance with China’s Good Manufacturing Practice (GMP) inspection regime is one of the most critical regulatory hurdles. The National Medical Products Administration (NMPA, formerly CFDA) has developed a rigorous framework for inspecting foreign drug factories that mirrors — and in some respects exceeds — international standards. Understanding the full scope of GMP inspection requirements, from pre-application preparation through post-inspection follow-up, is essential for any foreign pharma company planning to register drugs in China.

Overview of China’s GMP Regulatory Framework

China’s GMP standards are codified under the Drug Administration Law of the People’s Republic of China and its implementing regulations. The current GMP certification system, introduced in its modern form in 2011, underwent significant revision with the 2019 Drug Administration Law amendments and subsequent NMPA guidelines. Foreign drug factories are subject to the same GMP standards as domestic Chinese manufacturers, though the inspection process differs in several important respects.

The NMPA’s Center for Food and Drug Inspection (CFDI) is the primary body responsible for conducting GMP inspections of foreign manufacturers. Since 2018, the NMPA has significantly expanded its overseas inspection program, with the stated goal of aligning Chinese GMP standards with the Pharmaceutical Inspection Co-operation Scheme (PIC/S) framework, to which China formally applied for membership in 2021.

Trigger Events for Foreign GMP Inspections

Not every foreign drug factory undergoes an NMPA GMP inspection. There are several specific trigger events that may result in an overseas inspection being scheduled:

1. New Drug Registration Applications

When a foreign company submits a New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) to the NMPA, the authority may schedule a GMP inspection of the manufacturing site. For Class 1 innovative drugs and Class 2 improved new drugs, an on-site inspection is highly likely. For generic drugs, the probability of inspection depends on the drug’s therapeutic category, manufacturing complexity, and the NMPA’s risk assessment.

2. Pre-Approval Inspections (PAI)

Before granting marketing authorization for a new drug, the NMPA typically conducts a Pre-Approval Inspection (PAI) that covers both GMP compliance and the accuracy of the drug’s registration dossier. This inspection verifies that the manufacturing process described in the application matches actual production practices.

3. Routine Periodic Inspections

Once a foreign drug is approved for the Chinese market, the manufacturing site may be subject to periodic GMP inspections, generally every three to five years. The frequency depends on the drug’s risk classification, the manufacturer’s compliance history, and any recent quality incidents.

4. For-Cause Inspections

If the NMPA receives adverse drug reaction reports, quality defect notifications, or compliance concerns from other regulatory bodies (such as the FDA or EMA), it may initiate a for-cause GMP inspection of the foreign manufacturing site.

5. Renewal of Drug Registration Certificates

Drug registration certificates in China are valid for five years. Upon renewal, the NMPA may require a new GMP inspection, particularly if there have been significant changes to the manufacturing process or facility since the last inspection.

Key Requirements for GMP Compliance

The NMPA’s GMP standards for pharmaceutical manufacturing cover the following core areas, all of which are evaluated during an overseas inspection:

Quality Management System

Foreign manufacturers must demonstrate a comprehensive quality management system that includes a qualified person (QP) responsible for quality assurance, a robust change control system, deviation management, corrective and preventive actions (CAPA), and a documented quality risk management approach consistent with ICH Q9 guidelines.

Facility and Equipment

The manufacturing facility must be designed, constructed, and maintained according to GMP principles. This includes appropriate cleanroom classifications (ISO 7 or better for sterile products), validated HVAC systems, environmental monitoring programs, and equipment qualification (IQ/OQ/PQ). The NMPA pays particular attention to cross-contamination prevention measures, especially for high-potency drugs, penicillins, cephalosporins, and biological products requiring dedicated facilities.

Production and Process Controls

Manufacturing processes must be validated according to NMPA guidelines. The CFDI expects to see process validation protocols and reports, batch record reviews, in-process control testing, and a validated cleaning procedure. Process validation should cover at least three consecutive commercial-scale batches.

Laboratory Controls

Quality control laboratories must be GMP-compliant, with validated analytical methods (which may differ from USP/EP methods if Chinese Pharmacopoeia methods are required), properly qualified equipment, and a comprehensive stability testing program. The NMPA places strong emphasis on the Chinese Pharmacopoeia (ChP) as the reference standard for testing methods where applicable.

Materials Management

Foreign manufacturers must have systems in place for supplier qualification, incoming material testing, and traceability of all raw materials, excipients, and packaging components. For imported drugs, the NMPA also requires documentation of the supply chain from raw material source to finished product.

The Overseas Inspection Process Step by Step

Step 1: Notification

The NMPA’s CFDI typically notifies the foreign manufacturer 30 to 60 days in advance of an overseas inspection. The notification includes the proposed inspection dates, scope, and team composition. Unlike domestic inspections, where unannounced inspections are increasingly common, overseas inspections are almost always announced to allow for logistical arrangements.

Step 2: Document Submission

Prior to the inspection, the manufacturer must submit a Site Master File (SMF) and supporting documentation as requested by the inspection team. Documents should be provided in both English and Chinese, or at minimum accompanied by certified Chinese translations. Key documents include the manufacturing license (or equivalent), product dossiers, quality management system documentation, and previous inspection reports from other regulators.

Step 3: On-Site Inspection

An NMPA overseas inspection team typically consists of two to four inspectors, including at least one GMP specialist and one drug registration specialist. The inspection lasts three to five days on average, though complex facilities or products may require longer. The inspection follows standard GMP audit practices: an opening meeting, facility tour, document review, interviews with key personnel, and a closing meeting.

Step 4: Inspection Report and Classification

After the inspection, the CFDI issues an inspection report with one of three classifications:

• Pass: No critical or major deficiencies identified. The manufacturer receives GMP certification.
• Conditional Pass: One or more major deficiencies identified that can be corrected within a specified timeframe (typically 30 to 90 days). The manufacturer submits a corrective action plan and evidence of remediation.
• Fail: Critical deficiencies identified that pose a significant risk to product quality or patient safety. The drug registration application may be rejected, or existing marketing authorization may be suspended.

Step 5: Follow-Up

For conditional pass outcomes, the manufacturer must submit a detailed CAPA report with supporting evidence. The CFDI may conduct a follow-up inspection (remote or on-site) to verify remediation. Failure to adequately address deficiencies can result in downgrade to a fail classification.

Common Deficiencies Found in Foreign GMP Inspections

Analysis of NMPA inspection findings for foreign manufacturers reveals several recurring themes:

1. Data integrity issues: Incomplete or unreliable laboratory data, lack of audit trails on computerized systems, and inadequate data governance policies. This is the single most common deficiency area.
2. Cross-contamination risks: Inadequate segregation of manufacturing areas for different product types, particularly for highly potent or sensitizing compounds.
3. Validation gaps: Insufficient process validation, cleaning validation, or method validation specific to the Chinese market requirements.
4. Stability data deficiencies: Incomplete or missing stability data under Chinese climatic conditions (Zone IVa), which may differ from data generated for other markets.
5. Supplier management weaknesses: Inadequate qualification of raw material suppliers, particularly for active pharmaceutical ingredients (APIs) sourced from third parties.
6. Deviation and OOS handling: Poor investigation of out-of-specification (OOS) results and inadequate root cause analysis for deviations.

Mutual Recognition and Remote Inspection Developments

China has been progressively expanding its mutual recognition of GMP inspections. As of 2026, the NMPA recognizes GMP inspections conducted by certain foreign regulatory authorities under specific bilateral agreements. However, these mutual recognition arrangements are limited and do not eliminate the need for a dedicated NMPA inspection in most cases.

Since the COVID-19 pandemic, the NMPA has also developed a framework for remote GMP inspections using video conferencing, document sharing platforms, and live video feeds of manufacturing areas. While remote inspections became more common during travel restrictions, the NMPA has indicated that on-site overseas inspections will remain the standard for high-risk products and new drug applications, with remote inspections reserved for lower-risk products and follow-up assessments.

Preparing for a Successful GMP Inspection

Foreign drug manufacturers seeking to pass an NMPA GMP inspection should take the following preparatory steps:

1. Conduct a gap analysis: Compare existing GMP systems against NMPA-specific requirements, with particular attention to data integrity, Chinese Pharmacopoeia testing methods, and validation documentation.
2. Engage a local regulatory consultant: A Chinese regulatory affairs professional can provide invaluable guidance on documentation formatting, translation quality, and inspection protocol nuances.
3. Prepare Chinese-language documentation: Ensure that the Site Master File, SOPs, batch records, and key quality documents are available in high-quality Chinese translation.
4. Conduct a mock inspection: Simulate the NMPA inspection process with a qualified consultant who understands CFDI inspection practices and common deficiency areas.
5. Review data integrity systems: Verify that all computerized systems have appropriate audit trails, user access controls, and data backup procedures that meet NMPA expectations.
6. Establish a CAPA readiness plan: Prepare a framework for responding to inspection findings within the NMPA’s required timelines, including root cause analysis capabilities.

Conclusion

The NMPA’s GMP inspection requirements for foreign drug factories represent a comprehensive regulatory framework that continues to evolve toward international standards. While the process is rigorous and resource-intensive, successful navigation of the GMP inspection pathway is essential for any foreign pharmaceutical company seeking to establish or maintain a presence in the Chinese market. By understanding the trigger events, preparation requirements, inspection procedures, and common pitfalls, foreign manufacturers can approach the NMPA GMP inspection process with confidence. As China continues to harmonize its pharmaceutical regulatory system with global standards through PIC/S membership efforts and mutual recognition agreements, the inspection landscape will continue to evolve — making ongoing regulatory monitoring a critical success factor.

Disclaimer: This article provides general guidance and does not constitute legal or regulatory advice. Foreign pharmaceutical companies should consult with qualified regulatory affairs professionals and legal counsel familiar with Chinese pharmaceutical regulations for their specific circumstances.